Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN60,9560,98-0,67
Msft-1,00
Nokia3,75053,7995-0,41
IBM0,38
Mercedes-Benz Group AG57,5357,550,77
PFE-0,27
19.09.2024 1:38:53
Indexy online
AD Index online
select
AD Index online
 

  • 18.09.2024
Biocryst Pharm (BCRX.O, NASDAQ Cons)
Závěr k 18.9.2024 Změna (%) Změna (USD) Objem obchodů (ks)
7,96 0,51 0,04 1 754 233
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.09.2024
Popis společnosti
Obecné informace
Název společnostiBioCryst Pharmaceuticals Inc
TickerBCRX
Kmenové akcie:Ordinary Shares
RICBCRX.O
ISINUS09058V1035
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.06.2024
Počet zaměstnanců k 31.12.2023 536
Akcie v oběhu k 31.07.2024 206 885 936
MěnaUSD
Kontaktní informace
Ulice4505 Emperor Blvd Ste 200
MěstoDURHAM
PSČ27703-8457
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon19 198 591 302
Fax19198591314

Business Summary: BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Financial Summary: BRIEF: For the six months ended 30 June 2024, BioCryst Pharmaceuticals Inc revenues increased 34% to $202.1M. Net loss decreased 63% to $48.1M. Revenues reflect Product sales increase from $68.2M to $198.6M, Collaborative and other research increase from $612K to $3.5M. Lower net loss reflects Loss on extinguishment of debt decrease from $29M (expense) to $0K, Research and development decrease of 16% to $84.1M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in Biotechnology
NAICS1997Biological Product (except Diagnostic) Manufacturing
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICBiological Prod's Not Diagnostic
SICBiological Prod's Not Diagnostic
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 19.09.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorJon Stonehouse6313.07.200705.01.2007
Chief Financial OfficerAnthony Doyle4402.04.202002.04.2020
Chief Medical OfficerDonald Fong-05.09.202405.09.2024
Chief Commercial OfficerCharles Gayer5315.01.202015.01.2020
Chief Development OfficerWilliam Sheridan6901.07.2008
Chief Research & Development OfficerHelen Thackray5522.03.202122.03.2021
Chief Legal Officer, Corporate SecretaryAlane Barnes5801.01.2013